secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2026-09-02T20:45:37+00:00
Accession:  0001477932-26-005359
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx gets Lind waiver for unlimited ATM sales; conversion price set at $0.44
--------------------------------------------------------------------------------

- Lind consents to all ATM sales, removing $10M annual cap; waives related defaults and remedies under Purchase Agreement and Notes.
- Conversion price of $7.5M (May 2025) and $2.4M (Jan 2026) senior secured notes fixed at $0.44; warrant exercise price set at $0.572.
- Lind waives anti-dilution adjustments to Notes/Warrants for ATM sales after Aug 28, 2026; prior adjustments accounted for through that date.
- Company still must apply 20% of ATM proceeds (above exempted amounts) toward note repayment per Section 5.7 of Purchase Agreement.
- Waiver dated Sept 2, 2026; CEO Cameron Reynolds signed for VolitionRx.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793226005359/0001477932-26-005359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793226005359/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-005359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer